CSF2 and myeloproliferative disorder: Finally, the anti-GM-CSF antibody lenzilumab has been shown to be safe and moderately effective with an ORR of 33.3% by MDS/MPN IWG response criteria in a phase I trial of 15 CMML patients (NCT02546284) [133].